Systemic Use of Bevacizumab for Recurrent Respiratory Papillomatosis: Who, What, Where, When, and Why?
Open Access
- 11 May 2022
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 133 (1) , 2-3
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult PopulationThe Laryngoscope, 2021
- Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus StatementThe Laryngoscope, 2021
- Systemic Bevacizumab (Avastin) for Juvenile‐Onset Recurrent Respiratory Papillomatosis: A Systematic ReviewThe Laryngoscope, 2020
- Systemic bevacizumab for recurrent respiratory papillomatosis: A national surveyThe Laryngoscope, 2017
- Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosisOncology Letters, 2014